The study underscores a troubling reality: although clinical consensus strongly advocates for the administration of medication for opioid use disorder (MOUD) in all pregnant individuals diagnosed with OUD, fewer than half receive such treatment. MOUD, which includes medications such as methadone, buprenorphine, and naltrexone, has been rigorously validated as the gold-standard intervention for managing opioid dependence during pregnancy. These medications are endorsed by major professional bodies, including the American College of Obstetricians and Gynecologists, due to their demonstrated benefits in improving both maternal and neonatal outcomes compared to untreated OUD or detoxification protocols.

Between 2016 and 2020, analysis of a vast commercial insurance claims database—the Merative MarketScan Commercial Claims and Encounters Database—showed that approximately 0.3 percent of pregnant and postpartum women were diagnosed with OUD. This dataset comprised nearly one million pregnancies, thereby providing a uniquely large and representative sample of insured individuals across the United States. The researchers meticulously tracked diagnostic and treatment claims, yielding granular insights into the patterns and timing of OUD diagnosis and MOUD utilization.

A pivotal finding from the study is that less than half (around 43 percent) of pregnant women who were diagnosed with OUD either prior to or during pregnancy actually received MOUD. This treatment gap raises critical concerns about missed clinical opportunities and systemic barriers to care delivery. Particularly noteworthy is the timing of diagnosis: women identified with OUD before pregnancy were substantially more likely to receive MOUD compared to those diagnosed during pregnancy, emphasizing the crucial need for early detection and intervention.

The disparity in MOUD uptake is compounded by geographic and demographic factors. Women residing in the Southern United States were 14 percent less likely to receive MOUD than their counterparts in the Northeast, highlighting regional differences in healthcare access and provider practices. The study also revealed that younger pregnant individuals and those living in non-metropolitan areas had higher rates of OUD diagnosis but did not necessarily receive proportional increases in treatment. These findings point toward entrenched structural and social determinants that influence both the diagnosis and management of OUD in pregnancy.

Mental health status emerged as another complex factor influencing treatment patterns. Pregnant women with multiple mental health conditions were more likely to receive MOUD, whereas those with chronic pain or concurrent substance use disorders paradoxically had lower rates of treatment uptake. This dichotomy suggests nuanced clinical decision-making processes and potential challenges in integrating care for comorbidities.

The stark underutilization of MOUD during pregnancy is particularly alarming given the well-documented risks of untreated opioid use disorder. When left untreated, OUD during pregnancy is linked with poor prenatal care engagement, increased incidence of pregnancy complications, and adverse maternal mental health outcomes. Furthermore, opioid overdose deaths among pregnant and postpartum individuals have escalated dramatically over the past decade, positioning overdose as one of the leading causes of pregnancy-associated mortality in the United States.

Clinical practices surrounding the prescription of MOUD also reveal significant gaps in provider knowledge and comfort. A related national survey highlighted by the study reports that only 33 percent of obstetrician-gynecologists routinely recommend MOUD for pregnant patients with OUD. This reluctance or inconsistency in clinical practice underscores the imperative for enhanced provider education, as well as improvements in systematic screening protocols within prenatal care frameworks to ensure more timely and equitable diagnosis.

Access considerations further complicate the landscape of MOUD delivery. Methadone treatment, while effective, is limited by federal regulations restricting its dispensation to specialized clinics that often require daily attendance. This model presents considerable barriers for pregnant women juggling childcare and other responsibilities. In contrast, buprenorphine—accounting for 84 percent of MOUD prescriptions in this study—can be prescribed in standard office-based settings, potentially offering more accessible options that align better with patients’ logistical needs. Emerging research on the safety profile of buprenorphine/naloxone combinations during pregnancy further expands the therapeutic armamentarium.

The study’s findings collectively stress that overcoming the ongoing public health challenge posed by opioid use disorder requires multifaceted strategies. These include expanding early and routine screening protocols, enhancing provider training and comfort with MOUD prescribing, addressing regional and systemic disparities, and tailoring treatment access to meet the diverse needs of pregnant individuals. Obstetricians, gynecologists, and primary care providers stand at the frontline of these efforts, tasked with ensuring that evidence-based care is not only available but actively delivered during this critical window.

This research also serves as a call to policymakers and healthcare systems to dismantle the obstacles that perpetuate the under-treatment of opioid use disorder in pregnancy. Strengthening insurance coverage policies, facilitating integration of behavioral health services, expanding telehealth and decentralized MOUD delivery models, and combatting stigma at both the community and provider levels are essential components of a comprehensive response.

In conclusion, while the safety and efficacy of MOUD during pregnancy are well-supported by clinical evidence, the real-world uptake of these treatments remains insufficient, placing both mothers and infants at avoidable risk. Addressing this gap is imperative to curbing the increasing toll of opioid-related morbidity and mortality in this vulnerable population. The Columbia University Mailman School of Public Health study lays a critical foundation for future research and intervention, illuminating pathways to improve outcomes through earlier diagnosis and more equitable treatment provision.

Subject of Research: Opioid use disorder and medication for opioid use disorder among pregnant women with commercial insurance in the United States.

Article Title: Opioid use disorder and medication for opioid use disorder among pregnant women with commercial insurance in the United States, 2016-2020.

News Publication Date: Not specified.

Web References: Not specified.

References: Not specified.

Image Credits: Not specified.

Keywords: Opioid use disorder, pregnancy, medication for opioid use disorder, MOUD, methadone, buprenorphine, maternal health, opioid overdose, public health, prenatal care, substance use disorder, healthcare disparities.

Opioid use disorder during pregnancy presents a profoundly complex clinical challenge marked by the necessity to balance effective addiction treatment with the safety of both mother and fetus. Traditional sublingual buprenorphine, administered daily beneath the tongue, has been the standard pharmacologic approach due to its efficacy in reducing illicit opioid use. However, sublingual treatment has notable limitations, including risks of medication misuse, adherence challenges, and pharmacokinetic fluctuations that cause daily peaks and troughs in blood levels. These fluctuations may inadequately suppress opioid cravings and withdrawal symptoms, potentially leading to intermittent use of illicit opioids during pregnancy.

The NIH-supported multicenter randomized clinical trial enrolled 140 pregnant participants diagnosed with OUD, who were randomized to receive either weekly subcutaneous extended-release buprenorphine injections or standard daily sublingual buprenorphine, with or without naloxone. The extended-release formulation, administered under the skin, offers a pharmacologically stable delivery system that maintains therapeutic buprenorphine plasma concentrations consistently throughout the week. Postpartum participants who were not breastfeeding were given the option to receive monthly extended-release treatments, thereby extending the study’s relevance beyond pregnancy into the critical postpartum period.

Urine drug screenings served as the objective metric for opioid abstinence throughout gestation and up to 12 months postpartum. Analysis revealed that participants receiving the weekly extended-release injections exhibited significantly higher rates of opioid abstinence during pregnancy when compared to the sublingual cohort. Importantly, these superior abstinence rates persisted into the postpartum period, where extended-release therapy was shown to be non-inferior. This finding addresses a major clinical need, as postpartum relapse in OUD is a considerable risk due to factors such as stress, physiological changes, and the demands of new motherhood.

Safety outcomes also favored the extended-release group. Although non-serious adverse events were comparably frequent between both groups, those events in the extended-release cohort were more frequently attributed to the medication itself during pregnancy. Contrastingly, serious maternal adverse events were significantly less common among those receiving injectable buprenorphine throughout the entire study period. The reduction in severe adverse events underscores the enhanced tolerability and potential safety benefits of the extended-release formulation, which may translate into fewer interruptions or discontinuations of therapy in clinical practice.

A crucial concern in managing OUD during pregnancy is the risk of neonatal opioid withdrawal syndrome (NOWS), a condition characterized by withdrawal symptoms in newborns exposed to opioids in utero. This trial found no statistically significant differences in NOWS outcomes between the injectable and sublingual treatment groups. This equivalency suggests that extended-release buprenorphine does not increase harm to neonates compared to traditional treatment, while simultaneously offering superior maternal opioid abstinence benefits.

Beyond its clinical implications, this trial marks a significant methodological milestone as the first randomized controlled study to evaluate extended-release buprenorphine specifically in pregnant and postpartum populations. Prior evidence had established the efficacy of extended-release formulations in non-pregnant adults, but this direct assessment during pregnancy is critical given the unique physiological, pharmacokinetic, and psychosocial factors in this demographic.

Mechanistically, the pharmacokinetics of extended-release buprenorphine enable a steady-state plasma concentration that mitigates the classic peak-trough fluctuations seen with sublingual dosing. This steady exposure more effectively attenuates opioid withdrawal symptoms and cravings, likely contributing to the enhanced abstinence observed. Furthermore, the weekly injection reduces the burden of daily dosing adherence, lowering the risk of missed doses or medication diversion, and thus potentially decreasing illicit opioid use.

Clinicians treating pregnant patients with OUD often face challenges with maintaining consistent adherence to daily medications. The extended-release injectable formulation presents a promising intervention to address this obstacle by simplifying treatment regimens and providing sustained medication coverage. This can enhance treatment retention and support more stable recovery trajectories during the vulnerable prenatal and postpartum timeframes.

The broader public health implications of these findings are substantial. The opioid overdose crisis remains a dire emergency in the United States and globally, with pregnant populations being particularly vulnerable to adverse outcomes. Improving treatment modalities that not only ensure maternal safety but also reduce fetal and neonatal risks is paramount. By validating extended-release buprenorphine’s safety and superior efficacy, this trial empowers clinicians and policymakers to incorporate this formulation into standard care guidelines for managing OUD in pregnancy.

This study also highlights the importance of ongoing NIH-funded research efforts within the NIH Helping to End Addiction Long-term® (NIH HEAL®) Initiative, which targets innovative strategies to combat substance use disorders. The clinical trial’s design, involving randomized allocation and robust follow-up through 12 months postpartum, exemplifies rigorous research methodologies essential for generating actionable evidence in complex populations.

In conclusion, the adoption of weekly injectable extended-release buprenorphine for pregnant individuals with OUD offers a transformative enhancement over daily sublingual administration. Its ability to achieve higher opioid abstinence rates safely, coupled with a comparable neonatal risk profile, positions this treatment as a vital weapon in the fight against the opioid epidemic affecting mothers and infants alike. Future research will be necessary to optimize dosing strategies, evaluate long-term maternal and child outcomes, and expand access to this therapy across diverse healthcare settings.

Subject of Research: Extended-release versus sublingual buprenorphine treatment efficacy and safety in opioid use disorder during pregnancy and postpartum.

Article Title: Extended-release versus Sublingual Buprenorphine in Pregnancy through 12-months Postpartum

News Publication Date: 16-Mar-2026

Web References:
https://doi.org/10.1001/jamainternmed.2026.0057
https://www.nih.gov/heal
https://www.nida.nih.gov

References:
TJ Winhusen, et al. Extended-release versus Sublingual Buprenorphine in Pregnancy through 12-months Postpartum. JAMA Internal Medicine. DOI: 10.1001/jamainternmed.2026.0057

Keywords: opioid use disorder, pregnancy, extended-release buprenorphine, sublingual buprenorphine, neonatal opioid withdrawal syndrome, clinical trial, pharmacokinetics, addiction treatment, maternal health, postpartum, drug adherence, NIH HEAL Initiative